Zonisamide in Epilepsy: A Pilot Study
Zonisamide in Epilepsy: A Pilot Study
复制标题
唑尼沙胺治疗癫痫：一项初步研究
DOI：
10.1111/j.1528-1157.1985.tb05408.x
复制
发表时间：
1985
期刊：
影响因子：
5.6
通讯作者：
R. Levy
中科院分区：
文献类型：
--
作者：
A. Wilensky;P. Friel;L. Ojemann;C. Dodrill;K. McCormick;R. Levy
总结：我们在一项对8名患有不受控制的部分性癫痫发作的成人进行的开放交叉初步研究中，比较了苯妥英基线单药治疗（8周）后唑尼沙胺单药治疗（12周）与卡马西平单药治疗（12周）。唑尼沙胺在5名受试者中具有明确的抗癫痫活性。在其中两例中，唑尼沙胺的反应上级苯妥英或卡马西平。第3例受试者在唑尼沙胺治疗后无癫痫发作，但在18天后因轻度史蒂文斯约翰逊综合征而退出研究。其他3名受试者因药物毒性而退出研究，主要表现为高级精神功能受损和癫痫发作增加。唑尼沙胺的最佳反应剂量约为6 mg/kg/天，血浆水平为20-30 mg/L。血浆浓度> 30 mg/L通常与毒性有关。唑尼沙胺的药代动力学是复杂的和非线性的，稳态血浆水平大约是单次给药研究预测值的三倍。
Summary: We compared zonisamide monotherapy (12 weeks) to carbamazepine monotherapy (12 Weeks) after phenytoin baseline monotherapy (8 weeks) in an open crossover pilot study of eight adults with uncontrolled partial seizures. Zonisamide had definite antiepilepitic activity in five subjects. In two of these, response to zonisamide was superior to that to either phenytoin or carbamazepine. A third subject became seizure free on zonisamide, but had to be withdrawn after 18 days because of mild stevens‐Johnson syndrome. The other three subjects were withdrawn from the study because of drug toxicity, manifested mainly by impaired higher mental function and increased seizures. The best response to zonisamide was at doses approximating 6 mg/kg/day, with plasma levels of 20–30 mg/L. Plasma levels of > 30 mg/L usually were associated with toxicity. the pharmacokinetics of zonisamide are complex and nonlinear, with steady‐state plasma levels being approximately three times higher than those predicted from a singledose study.